CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Lenalidomide 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00632359
NCT00632359Phase 2Completed
CompareCT.gov

A Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy - RV-CLL-PI-0270

M.D. Anderson Cancer Center·interventional·Posted Mar 10, 2008·Updated Feb 10, 2020

In Brief

A Phase 2 clinical trial evaluating Lenalidomide for Chronic Lymphocytic Leukemia. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if Revlimid (lenalidomide) can help to reduce the level of leukemia in your body. The safety of this drug will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 10, 2008
Enrollment StartFeb 1, 2008
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 18.3 years ago

Interventions

Lenalidomidedrug

10 mg daily given for 12 months